Open AccessSurvey of Adverse Events After The First Dose of The ChAdOx1 nCoV-19 Vaccine: A Single-Center Experience in Korea
Author(s) -
Je Eun Song,
Gang Bok Oh,
Hye Kyeong Park,
Sung-Soon Lee,
Yee Gyung Kwak
Publication year - 2021
Publication title -
infection and chemotherapy/gam'yeom gwa hwahag yo'beob/infection and chemotherapy
Language(s) - English
Resource type - Journals
eISSN - 2092-6448
pISSN - 1598-8112
DOI - 10.3947/ic.2021.0044
Subject(s) - medicine , myalgia , adverse effect , pandemic , vaccination , covid-19 , cross sectional study , health care , disease , virology , infectious disease (medical specialty) , pathology , economics , economic growth
Vaccination is an important strategy for controlling the coronavirus disease 2019 (COVID-19) pandemic. We conducted a web-based cross-sectional survey based on Google Forms to collect data on adverse events (AEs) after the first dose of the ChAdOx1 nCoV-19 vaccine for healthcare workers (HCWs). Among the 1,676 vaccinated HCWs, 59.5% (998/1,676) responded to the survey. In total, 809 (81.1%) respondents reported experiencing AEs. There were no serious AEs, such as anaphylaxis. The most common AE was pain at the injection site (76.2%), followed by fatigue (75.9%), myalgia (74.9%), and fever (58.4%). HCWs in the younger age group experienced significantly more AEs than in the older age group.